ISIN | LU2721086689 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Bellevue Funds (Lux) - Bellevue AI Health Bellevue Funds (Lux) - Bellevue AI Health I2 |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland |
Waystone Fund Services (Switzerland) SA Lausanne Phone: 0041213111781 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The Sub-fund is an actively managed equity fund. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two thirds of the net assets of Bellevue AI Health in a portfolio of carefully chosen shares and preference shares of companies whose business activities have a strong focus on the provision and/or use of artificial intelligence (AI) in the health sector or whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries. |
Peculiarities |
Current Price * | 145.81 EUR | 07.11.2024 |
---|---|---|
Previous Price * | 145.76 EUR | 06.11.2024 |
52 Week High * | 153.18 EUR | 30.08.2024 |
52 Week Low * | 132.42 EUR | 24.01.2024 |
NAV * | 145.81 EUR | 07.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 10,358,378 | |
Unit/Share Assets *** | ||
Trading Information SIX |
YTD Performance | - | - |
---|---|---|
YTD Performance (in CHF) | - | - |
1 month | -0.67% |
07.10.2024 - 07.11.2024
07.10.2024 07.11.2024 |
3 months | +2.30% |
07.08.2024 - 07.11.2024
07.08.2024 07.11.2024 |
6 months | +4.40% |
07.05.2024 - 07.11.2024
07.05.2024 07.11.2024 |
1 year | +10.11% |
24.01.2024 - 07.11.2024
24.01.2024 07.11.2024 |
2 years | - | - |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 8.96% | |
---|---|---|
UnitedHealth Group Inc | 7.93% | |
Novo Nordisk AS Class B | 4.95% | |
Johnson & Johnson | 4.32% | |
AbbVie Inc | 4.15% | |
Amgen Inc | 4.04% | |
Merck & Co Inc | 3.91% | |
Roche Holding AG | 3.46% | |
AstraZeneca PLC | 3.25% | |
Novartis AG Registered Shares | 3.16% | |
Last data update | 30.09.2024 |
TER *** | 1.46% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.80% |
Ongoing Charges *** | |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |